FEDERICO
PULIDO ORTEGA
Profesor asociado de Ciencias de la Salud
Universidad Autónoma de Madrid
Madrid, EspañaPublications en collaboration avec des chercheurs de Universidad Autónoma de Madrid (21)
2022
-
Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance
Open Forum Infectious Diseases, Vol. 9, Núm. 11
2019
-
HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study
Scientific Reports, Vol. 9, Núm. 1
-
Proteomic profile associated with loss of spontaneous human immunodeficiency virus type 1 elite control
Journal of Infectious Diseases, Vol. 219, Núm. 6, pp. 867-876
2016
2015
-
Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study
HIV Clinical Trials, Vol. 16, Núm. 1, pp. 43-48
2014
-
Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis
Journal of Acquired Immune Deficiency Syndromes, Vol. 66, Núm. 3, pp. 280-287
2013
-
Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: The TRIP study
HIV Clinical Trials, Vol. 14, Núm. 5, pp. 204-215
2011
-
Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy
Antiviral Therapy, Vol. 16, Núm. 1, pp. 59-65
-
Estudio farmacoeconómico de lopinavir/ritonavir en monoterapia en el ensayo clínico OK04
Pharmacoeconomics - Spanish Research Articles, Vol. 8, Núm. 3, pp. 85-97
-
Inappropriate claim of 'failure of ritonavir-boosted lopinavir monotherapy in HIV' in the Monotherapy Switzerland/Thailand (MOST) trial
AIDS
2009
-
HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations
Journal of Antimicrobial Chemotherapy, Vol. 64, Núm. 2, pp. 251-258
-
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-Week analysis
Journal of Acquired Immune Deficiency Syndromes, Vol. 51, Núm. 2, pp. 147-152
-
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression
Antiviral Therapy, Vol. 14, Núm. 2, pp. 195-201
2008
-
Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression
Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 6, pp. 1359-1361
-
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV
AIDS, Vol. 22, Núm. 2
2005
-
Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: Frequency, characterization and risk factors
Journal of Antimicrobial Chemotherapy, Vol. 55, Núm. 5, pp. 800-804
-
Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-Week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK study)
Journal of Acquired Immune Deficiency Syndromes, Vol. 40, Núm. 3, pp. 280-287
2004
-
Clinical, Virologic, and Immunologic Response to Efavirenz- or Protease Inhibitor-Based Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naive Patients with Advanced HIV Infection (EfaVIP 2 Study)
Journal of Acquired Immune Deficiency Syndromes, Vol. 35, Núm. 4, pp. 343-350